IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 160 participants.

Also called NCT06139328

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06139328
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Canada, Czechia, Germany, Hungary, Italy, New Zealand, Poland, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT06139328. Randomized; triple masking; primary purpose treatment. Start 2023-12-05 (actual); primary completion 2025-09-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
Acronym
IRI-EXPLORE
Intervention (Drug)
BI 765845
Intervention (Drug)
Placebo matching BI 765845
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06139328
Content hash
20bcd4b4f021d666768d7d5bf00399cb271d4e3a7bcf95d2d42b7594cbaab590